Objective: We aimed to investigate the prognostic significance of the preoperative platelet-to-lymphocyte ratio (PLR) in a cohort of clinically non-metastatic renal cell carcinoma (RCC).
INTRODUCTION
Renal cell carcinoma (RCC) accounts for 3% of all malignancies and clear cell RCC is the most prevalent type of RCC (1) . After curative treatment for RCC disease recurs in 10% -20% of patients (3) . Stratification of patients considering their risk of recurrence is important to discuss the treatment options and describe further follow-up (3) . Several prognostic parameters have been assessed in RCC and these include tumor stage, histologic type and Fuhrman grade (1, 4) . Novel molecular markers have been evaluated to improve the prognostic parameters' predictive correctness; nevertheless, none of them is recommended for daily practice due to limited accessibility and high costs. It is important to investigate useful prognostic markers for the prognosis of RCC patients.
The systemic inflammatory response in cancer patients plays an important role in disease progression and RCC is considered to be an immunological inflammatory malignancy (5) . Markers of inflammation such as C-reactive protein (CRP), erythrocyte sedimentation rate, neutrophil-to-lymphocyte ratio (NLR) and platelet-to-lymphocyte ratio (PLR) have gained prognostic value in patients with several malignancies (6) (7) (8) . Recent studies have demonstrated hematologic prognostic systems to predict prognosis in RCC patients (9, 10) ; however, their role in localized disease is less clear.
Preoperative measurements of lymphocytes, neutrophils and thrombocytesrepresent easily measured and inexpensive routine values. The PLRis associated with poor prognosis in several diseases (11) (12) (13) (14) (15) (16) (17) . There is argument that platelets might preserve circulating tumoral cells from destruction by the immune mechanism and facilitate adhesion of tumoral cells to the endothelium by the configuration of tumor thrombus (18) . In addition, lymphocytes affect the course of immune surveillance and lymphopenia is a representative marker of poor immune response (19) . A combined index using lymphocytes and platelets might be a potent prognostic marker for localized RCC. Nevertheless, data regarding the prognostic significance of the PLR in localized RCC are scarce.The aim of this study was to evaluate the effect of pre-surgical PLR on cancer-specific survival (CSS) in non-metastatic clear cell and non-clear cell RCC patients.
MATERIAL and METHODS
In this retrospective study, the medical records of 412 patients who underwent radical or partial nephrectomyfor clinically localized RCC at our department between 2006 and 2015 were reviewed. All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki Declaration. The study was approved by the internal review board (No. 2016/558) and informed consents were obtained from eligible patients.
The database include information on the demographics, preoperative laboratory parameters, pathological findings and survival of patients. Medical data were evaluated for age, gender, white blood cell (WBC) count within 7 days prior to surgery, follow-up time and cause of death. The complete blood counts were obtained by a hematology analyzer (Coulter Gen-S Hematology Analyzer, Beckman Coulter Corp, Hialeah, Florida). Pathological data included T, N and M stage according to 2010 TNM classification, tumor size, Fuhrman grade (20) , presence of renal vein invasion, vena caval invasion, Gerota fascia invasion, renal pelvic invasion, tumor necrosis, and lymph node status. The pathological assessment was performed by experienced pathologist.
Patients with distant metastasis (n=42) prior to treatment were excluded from the study for CSS analysis purposes. Patients with relevant pathologies affecting systemic inflammatory response (n=30), prior pre-surgical or post-surgical chemotherapy, radiotherapy or immunotherapy (n=22),hematologic disease (n=12), and mixed type RCC or familial RCC (n=8) were also excluded from the study. Finally, 298 patients were analyzed.
Postoperatively, every 6 month, all patients were assessed for the first two years and annually thereafter. The outcome measure of this study was CSS, calculated from the time ofsurgery to the time of RCC related death.
The data was analyzed with Statistical Package for Social Sciences (SPSS) version 22 (IBM Co., Armonk, NY, USA). Cancer-specific survivalwas estimated by Kaplan-Meier method with differences evaluated by log-rank test. The optimal cut-off value of PLR was detected using receiver operating curve analysis according to the maximum sensitivity and specificity. Backward stepwise multivariable Cox proportion analysis was performed to detect the effect of potential confounders such as age, tumor stage, Fuhrman grade, and other pathological variables on CSS. Comparison between categorical variables was performed using the chi-square test. Correlations were considered statistically significant at a p<0.05 level.
RESULTS
The clinicopathological characteristics of the entire study population are listed in Table 1 . The final cohort included 183 male (61.4%) and 115 female (38.6%). Median age at surgery was 61 years Table 2 ).
The mean platelet count was 286±133.3, the mean lymphocyte count was 2.0±0.8, and the the mean PLR was 157.7±92.4. Using the criteria referred above, we detected a cut-off value of 200 (AUC=0.715; sensitivity, 52.4%; specificity, 90.6%) in the ROC curvefor the PLR to be optimal to differentiate between patients' CSS that prompted us to select 200 as the optimal cut-off value for all statistical analysis to discriminate between low (≤200, n=250) and high (>200, n=48) PLR (Figure 1 ). Three-year and 5-year CSS probabilities were 91.1% and 86.6% in the PLR ≤ 200 group and 50.2% and 42.5% in the PLR > 200 group, respectively (log rank p value <0.001). Figure 2 shows the Kaplan-Meier curves for CSS. It displays that a high PLR is a consistent factor for poor prognosis in localized RCC patients (p<0.001). Subgroup analysis revealed significant correlations of the high PLR value on CSS for both clear cell and non-clear cell RCC types (p<0.001) ( Table 3) .
A high PLR value significantly associated with renal capsule infiltration, renal sinus involvement, renal pelvis involvement, angiolymphatic invasion, tumor necrosis, and lymph node involvement (Table 4) .
DISCUSSION
In this study, we studied the prognostic value of preoperative measurements of systemic inflammatory response in patients undergoing curative treatment for clear cell and non-clear cell RCC. Our study shows that PLR is an independent prognostic factor after treatment for localized clear cell and nonclear cell RCC. We also found that high PLR was associated with renal capsule infiltration, renal sinus involvement, renal pelvis involvement, angiolymphatic invasion, tumor necrosis, and lymph node involvement. Although serum hemoglobin, platelet count, lymphocyte count, neutrophil count, and NLR were significant markers in univariable model, they were not independently associated with survival in the multivariable analysis.
To the best of our knowledge, this study is the first study of PLR focused on localized clear cell RCC, together with non-clear cell RCC. Fox et al. (21) reported that the prognostic role of PLR was indicated in patients with advanced RCC. In non-metastatic disease, the prognostic significance of NLR and lymphocyte to monocyte ratio in patients after treatment were reported in many studies (22, 23) . Lee et al. (24) evaluated pretreatment PLR in patients with localized clear cell RCC. In their study, authors were not able to identify the PLR as an independent prognostic factor. However, our study demonstrate that PLR is an independent prognostic factor for localized clear cell and nonclear cell RCC. Lucca et al. (25) also analyzed the prognostic role of the PLR and reported that PLR was a significant prognostic factor in patients with localized clear cell RCC. The optimal cut point for the PLR was found 145 in their study. In our study, we found that the optimal cut-off for PLR is 200 with 52.4% sensitivity and 90.6% specificity. Since our findings may be particular to our cohort, additional external validation is essential.
As easily and cheaplymeasured routine inflammatory markers, they can serve asa helpful addition to standard prognostic indicators, such as TNM stage, Fuhrman grade and tumor size. The association between cancer and systemic inflammation has been hypothesized in the last few decades. The inflammatory response in patients with malignancy plays an important role in cancer progression. Grimes et al. (26) reported a systematic review of the prognostic role of inflammation in patients with localized RCC undergoing nephrectomy, recently. In their systematic review, they showed that elevated NLR to be associated with a poorer prognosis and they stated that evidence for PLR is minimal in this issue. Turkmen et al. (27) found a positive correlation of PLR, NLR and interleukin-6, tumor necrosis factor-α. They also reported that PLR was better than NLR at predicting inflammation. In our study, an elevated pre-surgical PLR was significantly associated with poor CSS; however, NLR is not independently associated with survival in the multivariable analysis. Our findings indicate that patients with an elevated PLR may benefit from more frequent follow-up protocols and more comprehensive treatment approaches.
Inflammation is open to induce protumorigenic microenvironment changes. The causes why PLR might be of prognostic relation in patients with RCC remain speculative in this section. One theory, thrombocytosis in malignancy may increase tumorigenesis by platelet derived growth factor, vascular endothelial growth factor and thrombospondin (28, 29) . According to another theory, platelets may protect circulating tumor cells from demolition by the immune system. Moreover, platelets facilitate adhesion of circulating tumor cells to the endothelium (18) . Second, lymphopenia is a surrogate indicator of poor immune response.The decreased lymphocytes also plays a role in inflammatory response to tumor biology. Menges et al. (30) reported that a decrease in CD +4 T lymphocyte can lead lymphocyte mediated immune reaction to malignancy.
Limitations of our study comprise the retrospective data evaluation with a relatively small population size. Second, no details was available concerning performance status and further inflammatory markers such as CRP and procalcitonin. Third, only the effect of PLR on CSS was assessed, but not on disease-free or recurrence-free survival. Despite these limitations, our findings suggest an important prognostic role of the PLR for patients with localized clear cell and nonclear cell RCC. However, further studies are required to confirm the relationship between PLR and prognosis in RCC patients.
CONCLUSION
Our study suggests that PLR is an independent prognostic factor for CSS after surgery in patients with clinically localized clear cell and non-clear cell RCC. PLR may provide a significant complement for clinical trial design and risk stratifying patients undergoing curative treatment for localized RCC.
